Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIlogy-6: Ramantamig + Daratumumab vs DVRd in Newly Diagnosed Multiple Myeloma
NCT07903272Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2026
- Primary completion
- Jan 2037
01
Overview
A Phase 3 trial of ramantamig in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
ramantamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07903272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07903272.